CEPI Grants $41.3 Million to Valneva to Enhance Global Access to First Chikungunya Vaccine The Coalition for Epidemic Preparedness Innovations and Valneva SE have expanded their partnership to enha...
Vaccines have been one of the most significant advancements in medical science, saving millions of lives by preventing infectious diseases. While the primary component of a vaccine is the antigen that stimulates an immune response, another crucial element often goes unnoticed: the adjuvant. What are Vaccin...
Find MoreModerna Reports Successful Phase III Trials for Dual Influenza and COVID-19 Vaccine Moderna, Inc. has reported that its Phase III trial for mRNA-1083, an experimental combination vaccine targeting both influenza and COVID-19, achieved its main objectives by generating a stronger immune response than the approved...
Find MoreSurvodutide Phase II trial Shows Groundbreaking Results in Liver Disease due to MASH, with Significant Improvements in Fibrosis Boehringer Ingelheim has reported that in a Phase II trial, a significant proportion of adults treated with survodutide (BI 456906), up to 83.0%, showed a notable enhancement in metabol...
Find MoreOver the past 15 years, an estimated 5 million cases of chikungunya have surfaced globally. This virus poses an escalating menace, having affected over half of the world’s nations. Recent cases in Spain, Italy, and France underscore its widespread reach. Additionally, the virus has expanded to new geographical area...
Find MoreSIBIONICS Received CE Mark for Its Ground-breaking GS1 Continuous Glucose Monitoring System On November 01, 2023, SIBIONICS, the world's third-largest Continuous Glucose Monitoring System (CGM) brand, received the CE Mark for its revolutionary GS1 CGM. This significant milestone marks a momentous achiev...
Find MorePositive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea The Global Antibiotic Research & Development Partnership (GARDP), in partnership with Innoviva, Inc. (Nasdaq: INVA), had announced a significant milestone. They revealed that zolif...
Find MoreUCB announces FDA approval of ZILBRYSQ for the Treatment of Adults with Generalized Myasthenia Gravis On the 17th of October 2023, UCB (Euronext Brussels: UCB) made an announcement regarding the approval of ZILBRYSQ® (zilucoplan) by the US FDA for the management of generalized myasthenia gravis (gMG) in adult pa...
Find MoreThe human immune system has a magnificent defense system that works continuously to protect the body from numerous infections and outside invaders. Maintaining a healthy immune response through the intricate interplay of cells, chemicals, and signaling pathways is essential for general health and well-being. Immuno...
Find MoreIn recent years, the healthcare and medical devices market has undergone a remarkable transformation, largely fueled by advancements in technology and growth in innovation. One of the major standout developments in the healthcare industry is the rise of the biosurgery market and the related product demand, whic...
Find MoreDevelopmental and Epileptic Encephalopathy (DEE) refers to a group of severe epilepsies that are cha.....
Find MoreSchizophrenia is a severe mental illness that interferes with a person's ability to think clearly, m.....
Find MoreIdiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of interstitial lung disease (ILD.....
Find MoreMultiple myeloma (MM) is a cancer of the blood that begins in the bone marrow. In myeloma, plasma ce.....
Find MoreAcute ischemic stroke (AIS) is a medical emergency caused by decreased blood flow to the brain, whic.....
Find MorePeanut Allergy accounts for the majority of severe food-associated allergic reactions. It is strictl.....
Find MoreLive Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!